LUC7L

LUC7L is a U1 snRNP-associated splicing factor that functions in 5' splice site recognition and selection (PMID:33852859, PMID:39979239). It crosslinks to weak 5' splice sites and to the 5' end of U1 snRNA, an activity that is evolutionarily conserved with the yeast Luc7p subunit of the U1 snRNP (PMID:33852859). Together with its paralog LUC7L2, LUC7L preferentially enhances splicing of a distinct class of 'right-handed' 5' splice sites that have stronger consensus on the intron side of the near-invariant /GU dinucleotide, and this specificity is conferred by its second zinc finger (ZnF2) domain (PMID:39979239, PMID:38719745). ZnF2 humanization studies in yeast establish that this domain dictates nonconsensus 5' splice site usage and influences the requirement for ATPase-driven U1 release, distinguishing LUC7L function from the divergent paralog LUC7L3 (PMID:38719745). LUC7L binds core spliceosomal factors and a distinct set of regulatory splicing factors through its arginine-serine-rich (RS) domain, which also directs its localization to nuclear speckles, and knockdown produces a largely unique program of dysregulated alternative splicing events (PMID:33852859, PMID:15474286). Beyond splicing, forced expression of LUC7L inhibits myogenic differentiation, and endogenous expression is downregulated during skeletal muscle differentiation (PMID:15474286).

1. 2001 Low

   Established LUC7L as a candidate splicing factor by identifying it as a widely transcribed RNA-binding protein with sequence similarity to the yeast U1 snRNP subunit Luc7p, framing the hypothesis that it participates in splicing.

   Evidence Genomic mapping, sequence analysis, and transcription profiling of human chromosome 16p13.3

   PMID:11170747

   Open questions at the time

   • Function inferred from sequence only, with no direct experiment on the protein
   • No demonstration of U1 snRNP association or splicing activity
2. 2004 Medium

   Showed that LUC7L is a nuclear speckle protein with a cellular phenotype, linking its RS domain to subnuclear targeting and its expression to control of myogenic differentiation.

   Evidence Gene trap identification, imaging of subcellular localization, and forced overexpression in Sol8/C2C12 myoblasts with differentiation assays

   PMID:15474286

   Open questions at the time

   • Mechanism connecting splicing activity to myogenesis not defined
   • Overexpression phenotype not corroborated by loss-of-function
3. 2021 Medium

   Defined LUC7L's biochemical role by showing it binds core and distinct regulatory splicing factors and crosslinks to weak 5' splice sites and U1 snRNA, establishing a conserved 5' splice site selection function and paralog-specific splicing programs.

   Evidence Co-immunoprecipitation/pulldown, CLIP RNA crosslinking, and knockdown with transcriptome analysis

   PMID:33852859

   Open questions at the time

   • Determinants of 5' splice site preference at sequence level not resolved
   • Distinct regulatory partners not individually validated
4. 2024 High

   Localized 5' splice site selection specificity to the ZnF2 domain and revealed functional divergence among human paralogs, including differential requirements for U1 release.

   Evidence ZnF domain humanization of yeast Luc7, reporter assays, transcriptome analysis, and genetic suppression of Prp28 ATPase mutations

   PMID:38719745

   Open questions at the time

   • Structural basis of ZnF2 splice-site discrimination not determined
   • LUC7L3 functional role left unexplained beyond non-complementation
5. 2025 High

   Defined a quantitative sequence rule for LUC7L target sites, showing it and LUC7L2 enhance 'right-handed' 5' splice sites with intron-side consensus, generalized across cell lines, leukemias, and plants.

   Evidence Knockdown plus transcriptome analysis, splice site mutagenesis, domain swaps, and analysis of LUC7L2 copy-number-variant leukemias with Arabidopsis validation

   PMID:39979239

   Open questions at the time

   • Physiological consequences of the right-handed splicing program in normal tissues not detailed
   • Direct disease causation by LUC7L itself not established
6. 2024 Low

   Implicated LUC7L in homeostatic cross-regulation, showing its productive splicing is controlled by a poison exon responsive to its spliceosomal partner PRPF40A.

   Evidence PRPF40A knockdown with transcriptome analysis in mouse neuroblastoma cells (preprint)

   PMID:bio_10.1101_2024.09.26.615222

   Open questions at the time

   • Single knockdown approach, preprint not peer-reviewed
   • Physical coupling of LUC7L and PRPF40A not directly demonstrated here
   • Poison exon regulation not confirmed in human cells

• How LUC7L's 5' splice site selection activity mechanistically governs cellular processes such as myogenesis, and whether its dysregulation directly drives disease, remain unresolved.
• No structural model of LUC7L bound to U1 snRNP or 5'SS
• Link between splicing program and myogenic phenotype unestablished
• No direct Mendelian or oncogenic causation demonstrated for LUC7L